ViaCell Announces Commencement of ViaCyte Pivotal Trial

CAMBRIDGE, Mass.--March 20, 2007--ViaCell, Inc. (Nasdaq: VIAC) today announced it has initiated a clinical trial to evaluate the safety and efficacy of ViaCyteSM, an investigational product being studied for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology.

ViaCell Announces Full Year and Fourth Quarter 2006 Financial Results and Provides 2007 Financial Guidance
Company Announces 30% ViaCord Sales Growth Quarter Over Quarter
Company Expects to Become Cash Flow Positive in First Half of 2008

CAMBRIDGE, Mass.--Feb. 27, 2007--ViaCell, Inc. (Nasdaq: VIAC) today reported financial results for the fourth quarter and twelve months ending December 31, 2006. Fourth quarter 2006 financial highlights are:

Sales of the ViaCord(R) product offering for the preservation and storage of umbilical cord blood were $14.4 million, representing a 30% increase over the fourth quarter of 2005; Operating expenses were $19.5 million; Net loss was $4.6 million, or $0.12 per share; Cash, cash equivalents and investments amounted to $51.2 million at year-end.

ViaCell Implements Automation Technology at ViaCord Processing Laboratory
Technology Represents First FDA Cleared System for Cord Blood Processing

Cambridge, MA--January 8, 2007--ViaCell, Inc. (Nasdaq: VIAC) today announced that it is integrating automation into its existing closed processing system at its processing laboratory for ViaCord®, a product offering that allows expectant families the opportunity to preserve their baby's umbilical cord blood for potential use by the child or related family member.